CACHD1 and metabolic dysfunction-associated steatohepatitis: In conclusion, CACHD1 is an early NASH-associated biomarker of liver preneoplastic and neoplastic lesions in STAM mice which could be used to investigate the mechanisms and potential inhibitors or promoters of hepatocarcinogenesis in this animal model, and a potential molecular target in DM/NASH-associated liver cancer.